Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations

Oncogene

Volumn 29, Issue 16, 2010, Pages 2337-2345

  Lauring, J ^a   Cosgrove, D P ^a   Fontana, S ^a   Gustin, J P ^a   Konishi, H ^a   Abukhdeir, A M ^a   Garay, J P ^a   Mohseni, M ^a   Wang, G M ^a   Higgins, M J ^a   Gorkin, D ^a   Reis, M ^a   Vogelstein, B ^a   Polyak, K ^b   Cowherd, M ^c   Buckhaults, P J ^c   Park, B H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akt1; Breast epithelial cells; Gene targeting; Knock in; Oncogene

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ESTROGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT GENE; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGENS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 77951586944     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.516     Document Type: Article

References (30)

1. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S et al. (2007). PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21: 2368-2370.
2. Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J et al. (2006). Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat 99: 23-33.
3. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A. (2007). Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 67: 8468-8476.
4. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775. (Pubitemid 41351083)
5. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M et al. (2008). AKT1(E17K) in human solid tumours. Oncogene 27: 5648-5650.
6. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
7. Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, Rechavi G. (2010). AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 116: 88-91.
8. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG et al. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99: 1265-1268.
9. Debnath J, Muthuswamy SK, Brugge JS. (2003a). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
10. Debnath J, Walker SJ, Brugge JS. (2003b). Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 163: 315-326.
11. Denley A, Gymnopoulos M, Hart JR, Jiang H, Zhao L, Vogt PK. (2008). Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods Enzymol 438: 291-305.
12. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE et al. (2008). Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 105: 20864-20869.
13. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M et al. (2009). Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325: 1261-1265.
14. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP et al. (2009). Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106: 2835-2840.
15. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ et al. (2006). PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932-5935.
16. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000.
17. Kim MS, Jeong EG, Yoo NJ, Lee SH. (2008). Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535.
18. Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP et al. (2007a). Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67: 8460-8467.
19. Konishi H, Lauring J, Garay JP, Karakas B, Abukhdeir AM, Gustin JP et al. (2007b). A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting. Nat Protoc 2: 2865-2874.
20. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q et al. (2008). The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumor-igenicity. Blood 111: 856-864.
21. Oda K, Stokoe D, Taketani Y, McCormick F. (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673.
22. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE et al. (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13: 3577-3584.
23. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
24. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y et al. (2009). The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145-148.
25. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
26. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
27. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32.
28. Wennstrom S, Downward J. (1999). Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279-4288.
29. Workman P. (2004). Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 32: 393-396.
30. Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garrett ES, Kwon TK et al. (2002). Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 161: 391-397.